|GRANTWAY
EN

Development and harmonisation of methodologies for assessing digital health technologies in Europe

European Comission

Share
Favorite
Feedback
Summary
12 January 2023
13 April 2023
-
-
-
For profit
Individuals
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
Afghanistan
Albania
Algeria
Angola
Argentina
Armenia
Aruba
Austria
Azerbaijan
Bangladesh
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bonaire
Bosnia and Herzegovina
Botswana
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Chad
Colombia
Comoros
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Faroe Islands
Fiji
Finland
France
French Polynesia
French Southern and Antarctic Territories
Gabon
Gambia
Georgia
Georgia
Germany
Ghana
Greece
Greenland
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Micronesia
Moldova
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nepal
Netherlands
New Caledonia
Nicaragua
Niger
Nigeria
North Korea
North Macedonia
Norway
Pakistan
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Republic of Côte d'Ivoire
Republic of the Congo
Romania
Rwanda
Saba
Saint Barthélemy
Saint Lucia
Saint Vincent and the Grenadines
Samoa
Sao Tome and Principe
Senegal
Serbia
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
St. Eustatius
St. Pierre and Miquelon
Sudan
Suriname
Sweden
Syria
Tajikistan
Tanzania
Thailand
Togo
Tonga
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
UK
Ukraine
Uzbekistan
Vanuatu
Venezuela
Vietnam
Wallis and Futuna
Yemen
Zambia
Zimbabwe
Research, Development and Innovation
Overview

ExpectedOutcome :

This topic aims at addressing digital transition challenges through supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. More specifically, this topic aims at supporting activities that are contributing to the following impact area: “High quality digital services for all”. To that end, proposals under this topic should aim to deliver results that are directed towards and contributing to all of the following expected outcomes:

  • Policymakers in the EU have at their disposal a methodological framework and standardised approaches for assessing digital health technologies, that helps them make evidence-based decisions regarding the introduction of digital health technologies in their health and care systems with added value for patients and society.
  • Regulators have access to robust, scientifically underpinned evaluation methodologies.
  • EU citizens gain faster access to safe and well-performing person-centred digital technologies and are empowered through these tools.
  • Health technology developers are better informed and dispose of more guidance on the evidence needed to demonstrate the added value of digital health technologies and have better insights on market predictability.
  • (Digital) Health Industry/digital health technology developers and HTA bodies can contribute to the development of EU harmonised Health Technology Assessment (HTA) rules based on common principles.
  • Improved cross-border use and interoperability of digital health tools and services throughout the EU and Associated Countries.
  • Increased trust in digital health technologies and better integration of digital health tools and services in health and care systems. Scope :

Digital health technologies have been driving a revolution in health and care ranging from general use of computers to algorithms designed to assist radiologists and radiotherapists in detecting and treating diseases, from robotic surgery to artificial intelligence, machine learning, computer aided decision models, and from mobile apps helping patients to self-manage their disease to electronic health records.

Digital health technologies are expected to further contribute to better people-centred health and care systems and have the vast potential to improve our ability to accurately prevent, diagnose and treat diseases.

However, assessing the added value and health benefits for patients and society pose a number of challenges in particular of methodological and technical nature. Best practice for common approaches in methodology for digital health are lacking, especially in the digital health tools that include artificial intelligence algorithms. A framework for the assessment of the digital transformation of health services and its impact is vital to generate the evidence required for decision-making on stimulating, using and/or funding digital health strategies at various levels in the health and care systems.

The Expert Panel on effective ways of investing in Health (EXPH) recommended in its report ‘Assessing the impact of digital transformation of health services[1]’, further investment in the development of assessment methodologies and in a European repository for evaluation methods and evidence of digital health services.

To date, such assessment frameworks are relatively scarce, especially those addressing the transformative aspects of healthcare delivery on the organisational and operational level.

The proposals are expected to develop and harmonise methodologies for assessing digital health technologies (including mhealth apps and telehealth, as well as Artificial Intelligence powered health technologies) in order to facilitate assessment of their added value at individual, health system and society levels and facilitate the cross-border deployment of digital health services within the EU. Existing Health Technology Assessment (HTA) methodology is well developed for health technologies such as medicinal products, but also for some categories of medical devices; however digitalisation raises new methodological challenges to the standardisation of assessment criteria such as privacy, cybersecurity, data storage and handling, interoperability, usability etc. Also including aspects like learning curves, iterative development of innovations, variability between settings, determining optimal timing of evaluations in the development process (maturity) are not yet solved.

Proposals are expected to build on existing frameworks such as (but not restricted to) ‘Model for Assessment of Telemedicine’ (MAST framework – Kidholm et al., 2012) and the results of previous EU-funded projects in particular (but not restricted to) COMED, project that already identified HTA challenges of telehealth and mhealth, and mHealth hub[2].

Proposals should consider involving the JRC to take advantage of its expertise on assessment frameworks of innovative health technologies and its activities at the interface between research and regulatory aspects and/or in translating assessment results into best practice recommendations anchored in EU policies. In that respect, the JRC is open to collaborate with any successful proposal after its approval.

The proposals should address all of the following activities:

  • Develop and/or expand a general methodological framework and standardised approaches to assess digital health technologies with a particular focus on criteria such as privacy, cybersecurity, data quality, data storage and handling, interoperability etc.;
  • Comply with the relevant requirements proposed in the European Health Data Space (EHDS) legal provisions;
  • Test the robustness of the developed methodologies on minimum 3 different digital health technology use cases;
  • Pilot the development of common specifications to the harmonisation of assessment frameworks (pre-market and post-market phases) throughout the EU and Associated Countries;
  • Include end-users of digital health technologies (be it professionals, care users or citizens), developers of digital health technologies, producers of health services, regulators and governments;
  • Collect best practice for common approaches in methodology for digital health technology assessment and develop an open access European repository for evaluation methods, studies, results and evidence of digital health technologies and services;
  • Contribute to a framework to evaluate and monitor whether the uptake and use of digital health services contribute to the overall goals of the health and care system;

Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.

[1] ASSESSING THE IMPACT OF DIGITAL TRANSFORMATION OF HEALTH SERVICES, Report of the Expert Panel on effective ways of investing in Health (EXPH) - https://ec.europa.eu/health/system/files/2019-11/022_digitaltransformation_en_0.pdf

[2] https://mhealth-hub.org/

Eligibility

General conditions

  1. Admissibility conditions: described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

  1. Eligible countries: described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .

  1. Other eligibility conditions: described in Annex B of the Work Programme General Annexes.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

The Joint Research Centre (JRC) may participate as member of the consortium selected for funding.

  1. Financial and operational capacity and exclusion: described in Annex C of the Work Programme General Annexes.

  2. Evaluation and award:

Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.

The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.

Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual .

Indicative timeline for evaluation and grant agreement: described in Annex F of the Work Programme General Annexes.

  1. Legal and financial set-up of the grants: described in Annex G of the Work Programme General Annexes.

Specific conditions

  1. Specific conditions: described in the specific topic of the Work Programme .

Documents

Call documents:

Standard application form (HE RIA, IA) - call-specific application form is available in the Submission System Standard evaluation form (HE RIA, IA)

HE General MGA v1.0 Information on clinical studies (HE)

Additional documents:

HE Main Work Programme 2023–2024 – 1. General Introduction HE Main Work Programme 2023–2024 – 4. Health HE Main Work Programme 2023–2024 – 13. General Annexes

HE Programme Guide HE Framework Programme and Rules for Participation Regulation 2021/695 HE Specific Programme Decision 2021/764 EU Financial Regulation Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment EU Grants AGA — Annotated Model Grant Agreement Funding & Tenders Portal Online Manual Funding & Tenders Portal Terms and Conditions Funding & Tenders Portal Privacy Statement

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023